Immunotherapy drug for treating HPV+ head and neck cancers hailed as "game-changer"
A new generation of “game-changing” drugs that harness the body’s immune system have been found to extend the lives of head and neck cancer sufferers. Ā The drug, Nivolumab, resulted in the doubling of one-year survival rates in clinical trials on HPV+ head and neck cancer patients. Ā Findings will be presented to the European Society for Medical Oncology Conference taking place in Copenhagen this week. Ā Nivolumab works by removing the switch so that immune cells can spot cancer cells and clear them out of the body. Ā Oracle’s Honorary Trustee, Professor Kevin Harrington, led this exciting trial.
Read the full article here https://www.bbc.co.uk/news/health-37588541